• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Sodium Lauryl Sulfate
Poloxamer 188
Methacrylic Acid-Ethylacrylate Copolymer 1:1(Type B)
Methacrylic Acid-Ethyl Acrylate Copolymer 1:1 Dispersion 30 Percent
Poly(Vinyl Acetate) Dispersion 30 Pre Cent
Magnesium Stearate

ValenzaBio, ProBioGen Enter Cell Line Pact

contractpharmaJuly 29, 2021

Tag: ValenzaBio , ProBioGen , VB119

ProBioGen and ValenzaBio have initiated a cell line development project involving the application of ProBioGen's GlymaxX technology.

ProBioGen will generate a new CHO-based expression system for ValenzaBio's VB119, a clinical-stage antibody. In addition to the CHO.RiGHT cell line development platform, ProBioGen will apply its ADCC modulating GlymaxX technology. GlymaxX enables a fine tuning of the fucose content of the antibody towards the originator molecule's fucose content. The GlymaxX technology offers flexibility in terms of fucosylation adjustment and enables its application for innovative molecules as well as for biosimilar projects.

Previous:ImmunoGenesis Opens Research Lab, Adds Key Roles

Next:Cerba Research Wins NIH Contract for Central Lab Services

Related News

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Manulife Hong Kong today announced a new partnership with New Frontier Group, one of the leading healthcare service providers in Greater China, to introduce cashless services for eligible customers through New Frontier Group's subsidiary, Prosper Health.

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

ValenzaBio, ProBioGen Enter Cell Line Pact | Pharmasources.com

Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis

PRNewswireDecember 13, 2024

Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis

You may like
More>>

PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides
CEFALEXINE cephalosporins

CEFALEXINE cephalosporins
CEFRADINE cephalosporins

CEFRADINE cephalosporins
CEFADROXIL cephalosporins

CEFADROXIL cephalosporins
CEFIXIME cephalosporins

CEFIXIME cephalosporins
CEFATHIAMIDINE cephalosporins

CEFATHIAMIDINE cephalosporins
CEFMINOX SODIUM cephalosporins

CEFMINOX SODIUM cephalosporins
CEFOXITIN SODIUM cephalosporins

CEFOXITIN SODIUM cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service